Sarah E. Stump
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah E. Stump has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Cook
University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science , Lexington, KY
1 shared publication Alexis R. Jones
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina
1 shared publicationAllison J. Schepers
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina
1 shared publicationAmber C King
Department of Pharmacy, Leukemia Service, Memorial Sloan Kettering Cancer Center, NY, USA
1 shared publicationAmber C. King
Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publicationAndrew Sharf
Bone Marrow Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC, USA
1 shared publication
Latest Publications
- 29 March 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (6) , 1411-1433
Real-world management of targeted therapies in chronic lymphocytic leukemia
The advent of novel targeted therapies, including B-cell receptor (BCR) pathway and B-cell lymphoma 2 (BCL2) inhibitors, has substantially changed the treatment paradigm for chronic lymphocytic leukemia (CLL). Although targeted therapies have improved outcomes compared to traditional chemoimmunotherapy in the front-line and relapsed or refractory settings, they are associated with resistance mutations and suboptimal outcomes in certain high-risk patients. Additionally, targeted therapies are associated with drug interactions and unique adverse effect profiles which can be challenging for patients and clinicians to manage. Ongoing studies continue to address questions regarding optimal sequencing of therapies, the role of treatment combinations, and the efficacy of next-generation novel agents. This review provides a comprehensive overview regarding the clinical management of targeted therapies for CLL and applies current literature to clinical practice.
- 29 March 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (6) , 1411-1433
Real-world management of targeted therapies in chronic lymphocytic leukemia
The advent of novel targeted therapies, including B-cell receptor (BCR) pathway and B-cell lymphoma 2 (BCL2) inhibitors, has substantially changed the treatment paradigm for chronic lymphocytic leukemia (CLL). Although targeted therapies have improved outcomes compared to traditional chemoimmunotherapy in the front-line and relapsed or refractory settings, they are associated with resistance mutations and suboptimal outcomes in certain high-risk patients. Additionally, targeted therapies are associated with drug interactions and unique adverse effect profiles which can be challenging for patients and clinicians to manage. Ongoing studies continue to address questions regarding optimal sequencing of therapies, the role of treatment combinations, and the efficacy of next-generation novel agents. This review provides a comprehensive overview regarding the clinical management of targeted therapies for CLL and applies current literature to clinical practice.
- Open Access
- 7 December 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (23) , 6034-6038
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Key Points: Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.
- 7 December 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (23) , 6034-6038
Open AccessA JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Key Points: Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.
- 16 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1590-1597
Evaluation of mobilization efficacy with an extended interval following plerixafor administration
Plerixafor is a hematopoietic stem cell mobilizing agent used in combination with granulocyte-colony stimulating factor to improve collection for autologous stem cell transplantation. Despite a recommendation for administration 11 h prior to apheresis per package labeling, logistical challenges lead many institutions to administer plerixafor at an extended interval. The purpose of this study was to determine if plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis. This was a retrospective evaluation of adult patients who received plerixafor based on an algorithm reserving daily plerixafor only for patients with a pre-apheresis CD34+ count of < 20 cells/µL (pre-apheresis plerixafor) or with a low CD34+ yield after the first apheresis session (rescue plerixafor). The primary outcome was achievement of a disease-specific collection goal of ≥ 6 ×106 CD34+ cells/kg for multiple myeloma and ≥ 4 ×106 CD34+ cells/kg for lymphoma. The mean interval between plerixafor administration and apheresis was 17 h in this study. Despite this extended interval, 64% of patients met their disease-specific collection goal. A minimum collection goal of ≥ 2 ×106 CD34+ cells/kg was achieved by 95% of patients. Mobilization remained efficient with a median of two days to complete collection. Based on this data, plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis.
- 16 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1590-1597
Evaluation of mobilization efficacy with an extended interval following plerixafor administration
Plerixafor is a hematopoietic stem cell mobilizing agent used in combination with granulocyte-colony stimulating factor to improve collection for autologous stem cell transplantation. Despite a recommendation for administration 11 h prior to apheresis per package labeling, logistical challenges lead many institutions to administer plerixafor at an extended interval. The purpose of this study was to determine if plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis. This was a retrospective evaluation of adult patients who received plerixafor based on an algorithm reserving daily plerixafor only for patients with a pre-apheresis CD34+ count of < 20 cells/µL (pre-apheresis plerixafor) or with a low CD34+ yield after the first apheresis session (rescue plerixafor). The primary outcome was achievement of a disease-specific collection goal of ≥ 6 ×106 CD34+ cells/kg for multiple myeloma and ≥ 4 ×106 CD34+ cells/kg for lymphoma. The mean interval between plerixafor administration and apheresis was 17 h in this study. Despite this extended interval, 64% of patients met their disease-specific collection goal. A minimum collection goal of ≥ 2 ×106 CD34+ cells/kg was achieved by 95% of patients. Mobilization remained efficient with a median of two days to complete collection. Based on this data, plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis.
- 6 March 2019
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 53 (9) , 922-932
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant
Objective: To review the literature for the treatment of classical and variant hairy cell leukemia (HCL, HCLv), evaluating efficacy, safety, and supportive care involved in the use of purine analogues (PAs), interferon, BRAF inhibitors, monoclonal antibodies, Bruton’s tyrosine kinase inhibitors, and new immunotoxin, moxetumomab pasudotox-tdfk (MPT). An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox. Study Selection and Data Extraction: Studies written in the English language were considered for this article. The significance of each article was determined by authors independently. Data Synthesis: HCL and HCLv are rare B-cell lymphoproliferative disorders, each with distinct biologies. Symptoms are characterized by pancytopenia and splenomegaly. Initial treatments for HCL were suboptimal, leading to minimal and transient remissions. PAs significantly improved outcomes, inducing remission in most patients. However, those with purine-resistant disease were left with a dearth of options, leading to implementation of vemurafenib for BRAF V600 mutated disease and chemoimmunotherapy with rituximab. Despite these advances, some HCL and a majority of HCLv patients experience relapse. Newer targeted agents offer promise for relapsed and refractory patients, including the recently approved MPT. Relevance to Patient Care and Clinical Practice: This review provides a comprehensive update on the pharmacological management of HCL and HCLv for clinicians who encounter patients with this rare disease. Conclusion: HCL and HCLv are uncommon lymphoid neoplasms that lead to a characteristic constellation of symptoms. The emergence of PAs and novel targeted agents have improved the likelihood and durability of responses for these patients.
- 6 March 2019
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 53 (9) , 922-932
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant
Objective: To review the literature for the treatment of classical and variant hairy cell leukemia (HCL, HCLv), evaluating efficacy, safety, and supportive care involved in the use of purine analogues (PAs), interferon, BRAF inhibitors, monoclonal antibodies, Bruton’s tyrosine kinase inhibitors, and new immunotoxin, moxetumomab pasudotox-tdfk (MPT). An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox. Study Selection and Data Extraction: Studies written in the English language were considered for this article. The significance of each article was determined by authors independently. Data Synthesis: HCL and HCLv are rare B-cell lymphoproliferative disorders, each with distinct biologies. Symptoms are characterized by pancytopenia and splenomegaly. Initial treatments for HCL were suboptimal, leading to minimal and transient remissions. PAs significantly improved outcomes, inducing remission in most patients. However, those with purine-resistant disease were left with a dearth of options, leading to implementation of vemurafenib for BRAF V600 mutated disease and chemoimmunotherapy with rituximab. Despite these advances, some HCL and a majority of HCLv patients experience relapse. Newer targeted agents offer promise for relapsed and refractory patients, including the recently approved MPT. Relevance to Patient Care and Clinical Practice: This review provides a comprehensive update on the pharmacological management of HCL and HCLv for clinicians who encounter patients with this rare disease. Conclusion: HCL and HCLv are uncommon lymphoid neoplasms that lead to a characteristic constellation of symptoms. The emergence of PAs and novel targeted agents have improved the likelihood and durability of responses for these patients.
- 28 June 2018
- Published by Springer Nature in Investigational New Drugs
- Vol. 36 (6) , 1143-1146
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient. Nine days following initiation of cabozantinib, the patient reported muscle cramps and serum CK had increased from levels 12 months earlier that were within normal limits to a grade 1 elevation of 244 units/L. Despite a dose reduction, her CK continued to rise over the next 2 months, leading to a peak CK of 914 units/L. Due to this grade 3 elevation, cabozantinib was permanently discontinued, and her CK subsequently returned to a grade 1 elevation within one week and then to baseline within 3 weeks. The temporal relationship between drug exposure and CK increase strongly suggests causality. To the authors’ knowledge, this is the first reported case of CK elevation attributed to cabozantinib, but cabozantinib-induced CK elevations could be under-reported, and providers should monitor for musculoskeletal complaints during cabozantinib therapy.
- 28 June 2018
- Published by Springer Nature in Investigational New Drugs
- Vol. 36 (6) , 1143-1146
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient. Nine days following initiation of cabozantinib, the patient reported muscle cramps and serum CK had increased from levels 12 months earlier that were within normal limits to a grade 1 elevation of 244 units/L. Despite a dose reduction, her CK continued to rise over the next 2 months, leading to a peak CK of 914 units/L. Due to this grade 3 elevation, cabozantinib was permanently discontinued, and her CK subsequently returned to a grade 1 elevation within one week and then to baseline within 3 weeks. The temporal relationship between drug exposure and CK increase strongly suggests causality. To the authors’ knowledge, this is the first reported case of CK elevation attributed to cabozantinib, but cabozantinib-induced CK elevations could be under-reported, and providers should monitor for musculoskeletal complaints during cabozantinib therapy.
- 27 November 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (12) , 1530-1536
Comparison of Weight‐Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies
Study Objective: Intravenous immunoglobulin (IVIG) is a weight‐based therapy used to treat and prevent infections in patients with hematologic malignancies. IVIG doses were calculated traditionally using actual body weight (ABW). However, limited pharmacokinetic data suggest dosing strategies using ideal body weight (IBW) or adjusted body weight (adjBW) may be appropriate given the small volume of distribution of IVIG. Our objective was to compare the effectiveness of using a precision‐dosing strategy (IBW or adjBW) with a traditional‐dosing strategy (ABW) for IVIG in patients with hematologic malignancies or those undergoing hematopoietic stem cell transplant, as well as to perform an IVIG drug use analysis.Design: Retrospective cohort study.Setting: Academic medical center.Patients: Between April 2014 and September 2016, 209 IVIG encounters met inclusion criteria for the primary outcome. Of those encounters, 125 were dosed using the traditional‐dosing strategy, and 84 used the precision‐dosing strategy.Measurements and Main Results: The primary outcome was infection rate within 30 days of IVIG administration. Secondary outcomes included 60‐day infection rate, immunoglobulin G (IgG)‐level response (IgG higher than 400 mg/dl), and realized and potential IVIG savings. No difference in 30‐day infection rate between precision‐ and traditional‐dosing strategies was identified (15.5% vs 16%, respectively, p=0.823). Similarly, no difference was identified in the 60‐day infection rate between groups (23.2% vs 19.8%, respectively, p=0.568). Levels of IgG obtained after IVIG repletion showed a treatment response rate of 86% in both groups. Use of a precision‐dosing strategy achieved $2600/month in institutional savings with the opportunity for an additional $4600/month in savings with complete adherence to this dosing strategy.Conclusion: No differences in infection rate and IgG‐level response were identified when a precision‐dosing strategy was used. Implementation of an IVIG precision‐dosing strategy provided institutional cost savings.
- 27 November 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (12) , 1530-1536
Comparison of Weight‐Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies
Study Objective: Intravenous immunoglobulin (IVIG) is a weight‐based therapy used to treat and prevent infections in patients with hematologic malignancies. IVIG doses were calculated traditionally using actual body weight (ABW). However, limited pharmacokinetic data suggest dosing strategies using ideal body weight (IBW) or adjusted body weight (adjBW) may be appropriate given the small volume of distribution of IVIG. Our objective was to compare the effectiveness of using a precision‐dosing strategy (IBW or adjBW) with a traditional‐dosing strategy (ABW) for IVIG in patients with hematologic malignancies or those undergoing hematopoietic stem cell transplant, as well as to perform an IVIG drug use analysis.Design: Retrospective cohort study.Setting: Academic medical center.Patients: Between April 2014 and September 2016, 209 IVIG encounters met inclusion criteria for the primary outcome. Of those encounters, 125 were dosed using the traditional‐dosing strategy, and 84 used the precision‐dosing strategy.Measurements and Main Results: The primary outcome was infection rate within 30 days of IVIG administration. Secondary outcomes included 60‐day infection rate, immunoglobulin G (IgG)‐level response (IgG higher than 400 mg/dl), and realized and potential IVIG savings. No difference in 30‐day infection rate between precision‐ and traditional‐dosing strategies was identified (15.5% vs 16%, respectively, p=0.823). Similarly, no difference was identified in the 60‐day infection rate between groups (23.2% vs 19.8%, respectively, p=0.568). Levels of IgG obtained after IVIG repletion showed a treatment response rate of 86% in both groups. Use of a precision‐dosing strategy achieved $2600/month in institutional savings with the opportunity for an additional $4600/month in savings with complete adherence to this dosing strategy.Conclusion: No differences in infection rate and IgG‐level response were identified when a precision‐dosing strategy was used. Implementation of an IVIG precision‐dosing strategy provided institutional cost savings.
- 15 August 2014
- Published by Springer Nature in Neurocritical Care
- Vol. 22 (1) , 89-92
Accuracy of Nimodipine Gel Extraction
Until recently, use of nimodipine in aneurysmal subarachnoid hemorrhage patients unable to swallow required extraction of gel from inside the commercially available capsule. Despite the Black-Box warning against inadvertent intravenous administration, bedside extraction of the gel from the capsule continues to be a common practice in some institutions. The accuracy of bedside extraction has not been formally evaluated. Twenty-eight nurses from the neurology and neurosurgical ICUs at a single center attempted to extract nimodipine gel from 2 capsules, each using the method currently approved by the US FDA. The primary outcome was mean weight of extracted gel per capsule, which was compared to both gel weight from batch compounded pharmacy syringes and a pre-calculated appropriate weight for 30 mg nimodipine gel. Simulated bedside extraction provided lower yield than pharmacy-compounded syringes (22.6 ± 4.6 mg vs 30.4 ± 0.59 mg, p = 0.001). Bedside extraction provided inconsistent and low yield (75.4 ± 15.32 % of possible dose extracted, p = 0.0001 for comparison of means between bedside extraction syringes and predicted gel weight). Pharmacy-compounded syringes provided consistent high yield (101.3 ± 2.0 % of possible dose extracted, p = 0.14 for comparison of means between pharmacy syringes and predicted gel weight). Combined with reports of significant patient harm and death with inadvertent intravenous administration, this study suggests that there is no role for bedside extraction of nimodipine in clinical practice.
- 15 August 2014
- Published by Springer Nature in Neurocritical Care
- Vol. 22 (1) , 89-92
Accuracy of Nimodipine Gel Extraction
Until recently, use of nimodipine in aneurysmal subarachnoid hemorrhage patients unable to swallow required extraction of gel from inside the commercially available capsule. Despite the Black-Box warning against inadvertent intravenous administration, bedside extraction of the gel from the capsule continues to be a common practice in some institutions. The accuracy of bedside extraction has not been formally evaluated. Twenty-eight nurses from the neurology and neurosurgical ICUs at a single center attempted to extract nimodipine gel from 2 capsules, each using the method currently approved by the US FDA. The primary outcome was mean weight of extracted gel per capsule, which was compared to both gel weight from batch compounded pharmacy syringes and a pre-calculated appropriate weight for 30 mg nimodipine gel. Simulated bedside extraction provided lower yield than pharmacy-compounded syringes (22.6 ± 4.6 mg vs 30.4 ± 0.59 mg, p = 0.001). Bedside extraction provided inconsistent and low yield (75.4 ± 15.32 % of possible dose extracted, p = 0.0001 for comparison of means between bedside extraction syringes and predicted gel weight). Pharmacy-compounded syringes provided consistent high yield (101.3 ± 2.0 % of possible dose extracted, p = 0.14 for comparison of means between pharmacy syringes and predicted gel weight). Combined with reports of significant patient harm and death with inadvertent intravenous administration, this study suggests that there is no role for bedside extraction of nimodipine in clinical practice.